Isis earns $7.5M milestone on PhII/III trial launch

Carlsbad, CA-based Isis Pharmaceuticals ($ISIS) nabbed a $7.5 million milestone payment from GlaxoSmithKline ($GSK) on the launch of a Phase II/III clinical study for ISIS-TTR, an antisense drug in development for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and heart tissues. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.